GLP-1 medications for weight loss: separating hope from hype

What did @wellnessbyhaleigh actually say?

Straightforwardly: the spoken audio in this video is not a personal health testimony. The transcript captures lyrics from a song, not a firsthand account of GLP-1 therapy. Lines like "it's a long way to do" and "better to run back" are musical phrases, not medical claims. The caption, however, tells a different story.

The caption is where the real content lives. Haleigh describes being "terrified" to start medication, wrestling with the fear that "it doesn't work" or that this would be "just another failed attempt." She also flags the stigma angle directly: "What will people think of me for needing medication to help me?" Those are real, relatable concerns shared by millions of people considering GLP-1 therapy. The hashtags, including #glp1community, #pcos, and #insulinresistance, point to a specific audience navigating weight management and metabolic health. So the video's actual claims live in the caption and framing, not in the audio.

Does the science back this up?

On the emotional experience of starting GLP-1 therapy? Yes, largely. The fears Haleigh describes map closely onto documented barriers to treatment initiation, and the eventual positive framing is consistent with real-world patient-reported outcomes.

Fear of medication failure is clinically well-documented. A 2022 analysis published in Obesity (Durkin et al.) found that prior weight loss failure was among the top psychological barriers to pursuing pharmacotherapy, even when patients were clinically eligible. The stigma concern she raises is also backed by data. Research from Puhl and Heuer (2010, Obesity Reviews) established that weight stigma actively delays people from seeking medical help, including medications. The hashtag #pcos is worth noting too. Semaglutide and tirzepatide are being studied for PCOS-related insulin resistance, though neither carries an FDA indication specifically for PCOS as of 2024. Her hashtag use implies a connection that the evidence is still building toward, not a settled clinical fact.

What did they get wrong (or right)?

Haleigh gets the emotional framing mostly right. The stigma around needing "medication to help" with weight is real, and her willingness to name it publicly does something useful. That said, the caption ends mid-sentence, so we cannot fully evaluate her conclusion or what she ultimately claims GLP-1 therapy did for her.

The implicit suggestion that this decision resolved her concerns deserves some scrutiny. GLP-1 medications work well for many people, but response rates vary significantly. A 2021 trial in The New England Journal of Medicine (Wilding et al.) showed that roughly 69 percent of participants on semaglutide 2.4mg lost at least 5 percent body weight, which means around 31 percent did not meet that threshold. "One of the best decisions" is a subjective statement and not inherently wrong, but it does flatten the reality that outcomes differ. The video also clusters PCOS, insulin resistance, and GLP-1 use together in the hashtags without explaining the relationship, which could mislead viewers into assuming these are interchangeable indications.

What should you actually know?

GLP-1 receptor agonists are legitimate, rigorously studied medications. But the decision to start them is more complicated than a before-and-after TikTok arc suggests. Here is what the evidence actually says.

• Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition.
• Neither is FDA-approved specifically for PCOS, though off-label use is being studied. A 2023 review in Frontiers in Endocrinology found promising signals for metabolic improvement in PCOS patients, but authors called for larger randomized trials before drawing firm conclusions.
• Medication stigma is a real barrier with measurable health consequences. Delaying appropriate treatment because of social judgment is not a neutral choice.
• Response to GLP-1 therapy is not guaranteed. Discussing realistic expectations with a licensed provider before starting is not pessimism, it is informed consent.
• Compounded versions of semaglutide or tirzepatide are not equivalent to FDA-approved brand-name drugs. Formulation, purity, and dosing standards differ. Do not assume interchangeability.